R. Ranuh, Sitti Radhiah, K. Sumitro, A. Darma, A. F. Athiyyah, Dwiyanti Puspitasari, D. Husada, A. Endaryanto, I. Surono, S. Sudarmo
{"title":"补充植物乳杆菌IS-10506对接受抗逆转录病毒治疗的人类免疫缺陷病毒感染儿童的辅助性T细胞和调节性T细胞的调节作用","authors":"R. Ranuh, Sitti Radhiah, K. Sumitro, A. Darma, A. F. Athiyyah, Dwiyanti Puspitasari, D. Husada, A. Endaryanto, I. Surono, S. Sudarmo","doi":"10.37290/ijpp2641-7197.17:42-46","DOIUrl":null,"url":null,"abstract":"Human immunodeficiency virus infection is associated with impairment of T helper 1, T helper 2, regulatory T, and T helper Type 17 homeostasis. While probiotics are widely known to improve these changes, understanding of their role on children’s immune system remains limited. In a randomized, double-blind, and placebo-controlled study conducted in Dr. Soetomo General Hospital, Surabaya from December 2012 to March 2013, we have investigated the effect of Lactobacillus plantarum IS-10506 on the regulation of T helper and regulatory T cell in children infected with human immunodeficiency virus receiving antiretroviral therapy for at least 6 months. Twenty-one human immunodeficiency virus infected children were divided into placebo and probiotic groups and L. plantarum IS-10506 was administered at a dose of 2.86 × 1010 colony forming units/day for 6 weeks. Levels of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin-17 were analyzed before and after treatment as an indicator of T-cell regulation of T helper and regulatory T cells. The results show a significant increase in transforming growth factor-β level ( p = 0.003) after administration of L. plantarum IS-10506 compared to placebo with the first-line antiretroviral therapy group. There was no reported adverse effect in this study. In conclusion, L. plantarum IS-10506 increases the regulation of regulatory T cell in human immunodeficiency virus infection in children receiving first-line antiretroviral therapy treatment.","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regulation of T Helper and Regulatory T Cells by Lactobacillus Plantarum IS-10506 Supplementation to Human Immunodeficiency Virus-Infected Children Under Antiretroviral Therapy\",\"authors\":\"R. Ranuh, Sitti Radhiah, K. Sumitro, A. Darma, A. F. Athiyyah, Dwiyanti Puspitasari, D. Husada, A. Endaryanto, I. Surono, S. Sudarmo\",\"doi\":\"10.37290/ijpp2641-7197.17:42-46\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Human immunodeficiency virus infection is associated with impairment of T helper 1, T helper 2, regulatory T, and T helper Type 17 homeostasis. While probiotics are widely known to improve these changes, understanding of their role on children’s immune system remains limited. In a randomized, double-blind, and placebo-controlled study conducted in Dr. Soetomo General Hospital, Surabaya from December 2012 to March 2013, we have investigated the effect of Lactobacillus plantarum IS-10506 on the regulation of T helper and regulatory T cell in children infected with human immunodeficiency virus receiving antiretroviral therapy for at least 6 months. Twenty-one human immunodeficiency virus infected children were divided into placebo and probiotic groups and L. plantarum IS-10506 was administered at a dose of 2.86 × 1010 colony forming units/day for 6 weeks. Levels of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin-17 were analyzed before and after treatment as an indicator of T-cell regulation of T helper and regulatory T cells. The results show a significant increase in transforming growth factor-β level ( p = 0.003) after administration of L. plantarum IS-10506 compared to placebo with the first-line antiretroviral therapy group. There was no reported adverse effect in this study. In conclusion, L. plantarum IS-10506 increases the regulation of regulatory T cell in human immunodeficiency virus infection in children receiving first-line antiretroviral therapy treatment.\",\"PeriodicalId\":53704,\"journal\":{\"name\":\"International Journal of Probiotics and Prebiotics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Probiotics and Prebiotics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37290/ijpp2641-7197.17:42-46\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Probiotics and Prebiotics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ijpp2641-7197.17:42-46","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
人类免疫缺陷病毒感染与辅助性T 1、辅助性T 2、调节性T和辅助性T 17型体内平衡受损有关。虽然益生菌被广泛认为可以改善这些变化,但对它们对儿童免疫系统的作用的理解仍然有限。2012年12月至2013年3月,我们在泗水Soetomo总医院进行了一项随机、双盲、安慰剂对照的研究,研究了植物乳杆菌IS-10506对接受抗逆转录病毒治疗至少6个月的人类免疫缺陷病毒感染儿童辅助性T细胞和调性T细胞的调节作用。将21例人类免疫缺陷病毒感染儿童分为安慰剂组和益生菌组,以2.86 × 1010菌落形成单位/天的剂量给予植物乳杆菌IS-10506,持续6周。分析治疗前后的干扰素-γ、白细胞介素-4、转化生长因子-β和白细胞介素-17水平,作为T细胞对辅助性T细胞和调节性T细胞调节的指标。结果显示,与安慰剂和一线抗逆转录病毒治疗组相比,给予植物乳杆菌IS-10506后转化生长因子-β水平显著升高(p = 0.003)。本研究未发现不良反应。总之,L. plantarum IS-10506在接受一线抗逆转录病毒治疗的儿童中增加了调节性T细胞在人类免疫缺陷病毒感染中的调节作用。
Regulation of T Helper and Regulatory T Cells by Lactobacillus Plantarum IS-10506 Supplementation to Human Immunodeficiency Virus-Infected Children Under Antiretroviral Therapy
Human immunodeficiency virus infection is associated with impairment of T helper 1, T helper 2, regulatory T, and T helper Type 17 homeostasis. While probiotics are widely known to improve these changes, understanding of their role on children’s immune system remains limited. In a randomized, double-blind, and placebo-controlled study conducted in Dr. Soetomo General Hospital, Surabaya from December 2012 to March 2013, we have investigated the effect of Lactobacillus plantarum IS-10506 on the regulation of T helper and regulatory T cell in children infected with human immunodeficiency virus receiving antiretroviral therapy for at least 6 months. Twenty-one human immunodeficiency virus infected children were divided into placebo and probiotic groups and L. plantarum IS-10506 was administered at a dose of 2.86 × 1010 colony forming units/day for 6 weeks. Levels of interferon-γ, interleukin-4, transforming growth factor-β, and interleukin-17 were analyzed before and after treatment as an indicator of T-cell regulation of T helper and regulatory T cells. The results show a significant increase in transforming growth factor-β level ( p = 0.003) after administration of L. plantarum IS-10506 compared to placebo with the first-line antiretroviral therapy group. There was no reported adverse effect in this study. In conclusion, L. plantarum IS-10506 increases the regulation of regulatory T cell in human immunodeficiency virus infection in children receiving first-line antiretroviral therapy treatment.
期刊介绍:
The International journal of Probiotics & Prebiotics publishes on online only in an open access format. This is a broad based international, interdisciplinary peer reviewed scientific journal for critical evaluation of research on prebiotics, probiotics and synbiotics. The major goal of this journal is to provide unbiased scientific data to students, researchers, healthcare providers, and the decision makers in the nutraceutical industry to help make informed choices about prebiotics, probiotics and synbiotics. To this end, the journal will publish original research articles and two types of review articles. First, we will publish a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, we will publish a critical evaluation of current human experimental data to help deliver products with medically proven use.